Implication of the galectin-3 in colorectal cancer development (about 325 Tunisian patients)

Bulletin du Cancer

Volumn 97, Issue 2, 2010, Pages

  Arfaoui Toumi, A ^a   Mahmoud, L Kria Ben ^a   Hmida, M Ben ^b   Khalfallah, M T ^a   Regaya Mzabi, S ^a   Bouraoui, S ^a  

^a MONGI SLIM HOSPITAL   (Tunisia)

^b UNIVERSITY OF TUNIS   (Tunisia)

Author keywords

Colon cancer; Galectin 3; Immunochemistry; Mucinous carcinomas

Indexed keywords

GALECTIN 3; MUCIN;

ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL ADHESION; CELL INTERACTION; COLON ADENOCARCINOMA; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; METASTASIS; MUCINOUS CARCINOMA; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION; TUNISIA;

EID: 77149130961     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1032     Document Type: Article

References (38)

1. Sablin MP, Italiano A, Spano JP. Colorectal cancers: prognostic and predictive factors of response to treatment. Bull Cancer 2009; 96: 417-23.
2. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006; 6: 46.
3. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2002; 1572: 285-93.
4. Raimond J, Zimonjic DB, Mignon C, Mattei M, Popescu NC, Monsigny M, et al. Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. Mamm Genome 1997; 9: 706-7.
5. Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson WR. Expression and function of galectin-3, a β galactoside-binging Lectin, in human monocytes and macrophages. Am J Pathol 1995; 147: 1016-28.
6. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2004; 19: 543-9.
7. Brondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994; 19: 20807-10.
8. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, et al. The NH2 terminus of galectin-3 governs cellular compartimentalization and fuction in cancer cells. Cancer Res 1999; 15: 6239-45.
9. Patterson RJ, Wang W, Wang JL. Understanding the biochemical activities of galectin-1 and galectin-3 in the nucleus. Glycoconj J 2004; 19: 499-506.
10. Lahm H, André S, Hoeflich A, Kaltner H, Siebert HC, Sordat B, et al. Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J 2004; 20: 227-38.
11. Guévremont M, Martel-Pelletier J, Boileau C, Liu FT, Richard M, Fernandes JC, et al. Galectin-3 surface expression on human adult chondrocytes: a potential substrate for collagenase-3. Ann Rheum Dis 2004; 63: 636-43.
12. Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1995; 75: 2818-26.
13. Nagy N, Legendre H, Engels O, André S, Kaltner H, Wasano K, et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 2003; 97: 1849-58.
14. Park JW, Voss PG, Grabski S, Wang JL, Patterson RJ. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res 2001; 27: 3595-602.
15. Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schüring MP, Salmon I, et al. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 2003; 16: 491-504.
16. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999; 81: 519-26.
17. Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000; 6: 4635-40.
18. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999; 85: 2475-84.
19. Castronovo V, Van Den Brûle FA, Jackers P, Clausse N, Liu FT, Gillet C, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 1996; 179: 43-8.
20. Idikio H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 1998; 12: 1287-90.
21. Van den Brûle FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, et al. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 1994; 8: 1096-9.
22. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 1996; 27: 1185-91.
23. Lotz MM, Andrews Jr CW, Korzelius CA, Lee EC, Steele Jr GD, Clarke A, et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 1993; 90: 3466-70.
24. Castronovo V, Campo E, van den Brûle FA, Claysmith AP, Cioce V, Liu FT, et al. Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 1992; 84: 1161-9.
25. Sanjuán X, Fernández PL, Castells A, Castronovo V, van den Brule F, Liu FT, et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 1997; 113: 1906-15.
26. Lee EC, Woo HJ, Korzelius CA, Steele Jr GD, Mercurio AM. Carbohydrate-binding protein 35 is the major cell-surface laminin-binding protein in colon carcinoma. Arch Surg 1991; 126: 1498-502.
27. Irimura T, Matsushita Y, Sutton RC, Carralero D, Ohannesian DW, Cleary KR, et al. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 1991; 51: 387-93.
28. Goh KL, Quek KF, Yeo GT, Hilmi IN, Lee CK, Hasnida N, et al. Colorectal cancer in Asians: a demographic and anatomic survey in Malaysian patients undergoing colonoscopy. Aliment Pharmacol Ther 2005; 22: 859-64.
29. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, et al. Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 1998; 115: 287-96.
30. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, et al. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2002; 8: 2570-5.
31. Huflejt ME, Jordan ET, Gitt MA, Barondes SH, Leffler H. Strikingly different localization galectin-3 and galectin-4 in human colon adenocarcinoma T84 cells. Am Soc Biochem Mol Biol 1996; 272: 14294-303.
32. Hittelet A, Legendre H, Nagy N, Bronckart Y, Pector JC, Salmon I, et al. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 2003; 103: 370-9.
33. Ochieng J, Green B, Evans S, James O, Warfield P. Modulation of the biologic functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta 1998; 1379: 97-106.
34. Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 6642-50.
35. Dudas SP, Yunker CK, Sternberg LR, Byrd JC, Bresalier RS. Expression of human intestinal mucin is modulated by the beta-galactoside binding protein galectin-3 in colon cancer. Gastroenterology 2002; 123: 817-26.
36. Bresalier RS, Byrd JC, Wang L, Raz A. Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3. Cancer Res 1996; 56: 4354-7.
37. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, et al. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 2002; 50: 392-401.
38. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006; 19: 59-68.